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Abstract
More than 50% of women with clinically apparent infection after mastectomy did not meet the 2020 National Healthcare Safety Network
(NHSN) definition for surgical site infection (SSI). Implant loss was similar whether the 2020 NHSN SSI definition was met or not, suggesting
equivalent adverse outcomes regardless of restriction to the surveillance definition.
(Received 10 June 2020; accepted 18 October 2020)

Surgical site infections (SSIs) are the most common healthcareassociated infection in the United States.1 Accurate SSI surveillance
and feedback to surgeons is essential to devise and implement
strategies to prevent postoperative infections. The Centers for
Disease Control and Prevention (CDC) National Healthcare
Safety Network (NHSN) definitions for deep-incisional and
organ-space SSIs have changed over time. For example, in 2013
the surveillance period for deep and organ space infections was
reduced from 1 year to 90 days for procedures including
implants.2,3 We sought to determine the impact of underreporting
infections after mastectomy using the 2020 NHSN SSI definition.
Methods
We conducted a retrospective cohort study using electronic health
record and billing data from 1 academic hospital and 1 community
hospital. We identified mastectomy admissions among women
aged ≥18 years from July 1, 2010 to June 30, 2015, using the
International Classification of Diseases, 9th Revision (ICD-9)
procedure codes (Supplementary Table 1 online) and verified
mastectomy by surgeon description.
Potential SSIs were identified by selecting records to review
based on performance of a microbiology culture or diagnosis
or procedure code suggestive of a wound complication within
180 days after mastectomy (Supplementary Table 1 online).
Infections were verified by review of outpatient and hospital
records for signs and symptoms of infection, intervening procedures, expansion history, and microbiology data.
We defined clinically apparent infections as infections that met
the pre-2013 NHSN definition or documented signs consistent
with SSI (eg, cellulitis necessitating implant removal). The
180-day SSI rates were calculated using the pre-2013, 2020
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NHSN, and clinical definitions (Supplementary Table 2 online).
The Fisher’s exact test was used to compare implant removal rates
and physician documentation of infection using SAS version 9.4
software (SAS Institute, Cary, NC). The study was approved by
the Washington University Human Research Protection Office
with a waiver of informed consent.
Results
In total, 1,902 women underwent mastectomy, of whom 148 developed clinically apparent infection at the surgical site within 180
days after operation. Infections in 69 women (46.6%) met the
2020 NHSN SSI criteria. Infections in 102 women (68.9%) met
the pre-2013 NHSN criteria, due to 33 infections after implant
reconstruction meeting the earlier SSI criteria (Table 1).
Of the 148 women with clinically apparent infections,
23 (15.5%) underwent mastectomy only and 125 (84.5%) underwent immediate reconstruction. Moreover, 100 women (67.6%)
had placement of tissue expander(s), 10 (6.8%) had permanent implant(s), and 15 (10.1%) underwent autologous flap
reconstruction.
The reasons for exclusion of clinically apparent infections based
on 2020 NHSN criteria (not mutually exclusive) included diagnosis
of a superficial incisional SSI >30 days after mastectomy (n = 22),
diagnosis of a deep incisional or organ-space SSI >90 days
after mastectomy (n = 19; 2 deep incisional, 17 organ-space),
manipulation of the surgical site after mastectomy in the absence
of signs/symptoms of infection [ie, surgical debridement (n = 18),
needle aspiration of seroma (n = 9), tissue expander access
(n = 40)], and negative intraoperative cultures (n = 14) (Table 2).
Methicillin-sensitive Staphylococcus aureus was the most commonly isolated etiologic organism, regardless of the onset timing
of infection (Supplementary Table 3 online).
Tissue expanders were accessed in 40 women before the onset
of clinically apparent infection, a median of 2 times (range, 1–7),
resulting in exclusion of 13 infections (32.5%) using the 2020
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Table 1. Impact of Changes in the National Healthcare Safety Network Surgical Site Infection (SSI) Definitions on the Number and Rate of Infections After Mastectomy

Total No. of
Clinically
Apparent
Infections
(n=148)a

No. of SSI
Meeting
the
Pre-2013
NHSN
Definition
(n=103)

No. of SSI meeting the
2020 NHSN definition,
(n=69), No. (No. Identified
By Surgeons)

Total No. of Clinically
Apparent Infections
Excluded by 2020 NHSN
Definition (n=79), No.
(No. identified by surgeons)

SSI Rate by
Clinically
Apparent
Infections

SSI Rate by
Pre-2013
NHSN
Definition

SSI Rate
by 2020
NHSN
Definition

683

23

12

12 (11)

11 (9)

3.37

1.76

1.76

Mastectomy
þ implant
reconstruction

1,122

110

86

53 (46)

57 (48)

9.80

7.66

4.72

Mastectomy
þ flap
reconstruction

97

15

4

4 (3)

11 (7)

15.46

4.12

4.12

Procedure
Mastectomy
only

Total
Surgeries

a
Clinically apparent infections at the surgical site includes infections that met the pre-2013 NHSN definition, plus any of the following within 180 d after surgery: infections with onset after a prior
diagnostic/therapeutic procedure, superficial infections >30 d, deep-incisional and organ-space infections >90 d with no implant, physician opened the deep wound in the presence of signs/
symptoms of infection (eg, erythema, warmth), or the physician described the wound as infected, despite negative culture results.

Table 2. Reasons for Not Meeting the 2020 National Healthcare Safety Network Definition of Surgical Site Infection (SSI)

Reason for Not Meeting Criteria

a

Mastectomy
Only
(n=11)

Mastectomy þ Implant
Reconstruction (n=57)

Mastectomy þ Flap
Reconstruction (n=11)

Total No. Of
Patients With
Signs Suggesting
Surgical
Site Infectiona
(n=79)

10

5

7

22

0

18

1

19

1

12

5

18

Superficial incisional SSI diagnosed >30 d
postoperatively
Deep incisional or organ space SSI
diagnosed > 90 d postoperatively
Prior procedure in the absence of
signs/symptoms of infection
Debridement of surgical site
Needle aspiration of breast
Accession of breast expanders
Culture negative microbiology from surgical
site
a

2

7

0

9

N/A

40

N/A

40

0

14

0

14

An infection may have been excluded for >1 of these reasons.

NSHN criteria. Expanders were last accessed a median 16 days
(range, 5–132) before infection onset. Overall, 9 women had
1–3 documented needle aspirations of a seroma, with the last aspiration a median of 11 days (range, 1–48) before infection onset.
Also, 18 women had debridement of necrotic skin flaps a median
of 13.5 days (range, 3–111) before infection onset.
Of the 14 women who failed to meet the NHSN criteria for SSI
due to a negative intraoperative culture, all had been treated with
antibiotics (median, 3 days) in the 2 weeks prior to implant
removal. Prior antibiotics before the negative intraoperative cultures included intravenous vancomycin, piperacillin/tazobactam,
and/or clindamycin (n = 8 women), or oral clindamycin, doxycycline, cephalexin, and/or sulfamethoxazole-trimethoprim (n = 6).
Of the 33 women with infection after implant reconstruction
that met the pre-2013 but not the 2020 NHSN SSI definition,
13 had an organ-space SSI >90 days after mastectomy, and
7 met the pre-2013 definition of deep-incisional or organ-space
SSI (3 deep incisional and 4 organ space) solely due to surgeon
diagnosis at the time of implant removal.

Of the 110 women who had expander or permanent implant
reconstruction, 94 (85.5%) had an infection at the surgical site
diagnosed by a surgeon and/or infectious diseases physician.
The percentage of women with physician-documented infection
was the same in women whose infection met the 2020 NHSN
SSI criteria (86.8%, 46 of 53) or whose infection did not meet
2020 criteria (84.2%, 48 of 57) (P = .790).
Overall, 102 of 110 women (92.7%) who developed clinically
apparent infection following immediate implant reconstruction
had their implants removed. These rates were 92.5% (49 of 53)
versus 93.0% (53 of 57) among those who met versus did not meet
the 2020 NHSN SSI criteria (P = 1.0).
Discussion
We reviewed records of women after mastectomy with or without
reconstruction and found that 53% of women with clinical infection did not meet the 2020 NHSN SSI definition. The number of
infections after implant reconstruction that met NHSN criteria
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decreased substantially after the criteria changes, which restricted
the surveillance period in 2013 and definitions of deep-incisional
and organ-space SSIs in 2014 and excluded infections after access
of tissue expanders in 2017. The differential impact of the definition changes on implant reconstruction SSIs is important because
immediate reconstruction has steadily increased during the past
20 years and tissue expanders account for the majority of
reconstruction procedures.4 The SSI rate after mastectomy is typically at least twice as high with versus without reconstruction,5
which is obfuscated by changes to the surveillance definition that
have differential impact on postimplant infections.
Manipulation of the surgical site post-mastectomy may
contribute to the risk of infection, depending on the frequency
and adherence to asepsis during manipulation. This is especially
true for breast tissue expander reconstruction, since the port
is accessed frequently for saline injection during expansion.
Surveillance with feedback of all infections involving the surgical
site post-mastectomy may alert surgeons and infection prevention
specialists of suboptimal practices, particularly regarding tissue
expansion, which could be targeted for infection prevention.6,7
In our cohort, systemic antibiotic therapy was administered in
women with implant reconstruction who presented with cellulitis,
in hopes of salvaging the implant.8 This likely led to negative intraoperative cultures at the time of implant removal in the 14 women
who met the clinical but not 2020 NHSN SSI definition. Most of
these infections met the pre-2013 NHSN definition due to physician diagnosis. Re-evaluation of physician diagnosis to define SSI
may need to be considered given the frequent empiric antibiotic
treatment in this population.
We have demonstrated that implant loss was virtually the same
in women with clinically diagnosed SSIs, regardless of whether the
2020 NHSN definition was met or not. Implant loss is important
from a patient perspective because it results in additional morbidity, procedures, hospital costs, and delays in completion of adjuvant therapy.9
Our study of 2 academically affiliated hospitals may not reflect
all community practices. The substantial changes in the NHSN SSI
definitions in the past decade2,3,10 have resulted in underreporting
of potentially preventable infections and underestimation of
infectious morbidity after mastectomy. Comprehensive infection
surveillance, particularly after breast implant reconstruction,
is essential to provide women with accurate information about
complication risks and to determine the need for additional infection prevention strategies.
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